CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers

  • Posted by: BIOCON

Biocon and Mylan to Present Final Overall Survival Data for OgivriTM(trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

  • Posted by: BIOCON

Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr

  • Posted by: BIOCON

Kiran Mazumdar-Shaw Conferred With Honorary Doctorate from Deakin University, Australia

  • Posted by: BIOCON

Biocon Appoints Dr. Christiane Hamacher as CEO Of Biocon Biologics India Limited

  • Posted by: BIOCON

Kiran Mazumdar-Shaw elected as Member of the National Academy of Engineering, U.S.

  • Posted by: BIOCON

Biocon Q3FY19 Earnings Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59%

  • Posted by: BIOCON

Biocon Foundation Dedicates Rejuvenated Hebbagodi Lake and Children’s Park to the Community

  • Posted by: BIOCON

Biocon Ranked 7th on Top Global Pharma & Biotech Employers List 2018

  • Posted by: BIOCON

Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167%

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>